The 52th Union World Conference On Lung Health

October 7, 2021 - 9:15am

MSH is pleased to participate in this year’s 52nd Union World Conference on Lung Health, taking place virtually from October 19-22, 2021.


With the unexpected COVID-19 pandemic, weaknesses have been exposed throughout health systems globally. COVID-19 has reversed public health gains made over the last decade, particularly in TB, MDR-TB, and HIV control. Over 90% of countries have reported disruptions in essential health services and 51% in TB services. 

Aligned with this year’s conference theme, Lung Health for All: Solutions for a New Era, MSH will present on the need for strong leadership to address COVID-19, recent progress toward TB elimination in Ethiopia, and successful diagnostic, preventive, and treatment services for vulnerable populations. While progress has been heavily impacted by the COVID-19 pandemic, TB strategies could provide insight to the COVID-19 response and vice versa. 

We invite you to learn more about MSH and our work at this year’s Union Conference: 

MSH Satellite Session: How Will COVID-19 Reshape Public Health Leadership in the Future?

Wednesday, October 20th Time: 12:15-1:45 pm EDT; 6:15-7:45 pm CEST

Join global leaders as they discuss innovative public health leadership and investment strategies to overcome COVID-19, prevent new pandemics, and protect gains in TB, MDR-TB, HIV, and lung health.

Featured Speakers: 

  • Sergio Carmona, Chief Medical Officer, FIND

  • Dr. Lucica Ditiu, Executive Director, STOP TB Partnership

  • Dr. Sabin Nsanzimana, Director General of Rwanda Biomedical Centre, Rwandan Ministry of Health

  • Dr. Eliud Wandwalo, Head of TB, The Global Fund

  • Marian W. Wentworth, President and CEO, MSH

Moderated by:

  • Dr. Tereza Kasaeva, Director of the World Health Organization Global TB Programme

  • Dr. Alaine Umubyeyi Nyaruhirira, Principal Technical Advisor for Laboratory Services at MSH 

Learn more about our Satellite Session



Guideline update on rapid molecular diagnostics for extrapulmonary TB: what is new and how far are countries implementing new tools?
Tuesday, October 19 at 10:30-11:50 am EDT; 4:30-5:50 pm CEST

Is TB elimination feasible in high TB burden countries in the foreseeable future? Reviewing progress and charting future directions
Wednesday, October 20th at 9:00-10:20 am EDT; 3:00-4:20 pm CEST
Leveraging existing platforms to ensure coordinated and improved diagnostics and care for HIV, TB, HPV, and COVID-19
Friday, October 22 at 6:30-7:50 am EDT; 12:30-1:50 pm CEST

Spotlight: Ethiopia’s USAID Eliminate TB Project

This year Ethiopia was removed from the WHO’s global list of 30 high-burden countries for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB), yet still remains on the WHO high-burden list for TB and HIV/TB. This achievement reflects the shift that MSH has taken: moving from TB control strategies, used for the past 15 years, to creating a pathway to TB elimination for Ethiopia through the USAID Eliminate TB Project.

At the symposium, Is TB elimination feasible in high TB burden countries in the foreseeable future?, the project will discuss Ethiopia’s consistent TB decline as the foundation of TB elimination. One TB elimination approach, pivoting to find hard-to-reach cases, especially in vulnerable and marginalized populations such as adolescents and in prison settings, will be a focal point. The project will compare case finding strategies in Ethiopia's prison settings to identify which is most successful. Poster presentations include the impact of COVID-19, contact screening, and diagnostic technology. 

Oral Presentation










The yield of different tuberculosis case finding strategies in the prison setting of Ethiopia
Thursday, October 21, 5:20-5:28 am EDT; 1:30-2:50 pm CEST


Poster Presentations 

  • The seasonality pattern of tuberculosis reversed during initial COVID-19 report in Ethiopia (ETBE)
  • About one-fourth of tuberculosis cases in Ethiopia are among the adolescent population
  • The value of tracing contacts of clinically diagnosed tuberculosis cases in high-TB-burden countries
  • The yield of drug-resistant tuberculosis contact screening in three regions of Ethiopia
  • Impact of COVID-19 on detection of drug-resistant tuberculosis in Ethiopia
  • GeneXpert testing and utilization rates declined by one-fourth after the COVID-19 pandemic in Ethiopia
  • Variations in yield of TB among different health service units of health facilities
  • Improved tuberculosis preventive therapy for contacts during COVID-19 in Ethiopia